What's Happening?
Vir Biotechnology, Inc. has reported positive topline results from its pivotal Phase 3 ECLIPSE 1 trial, evaluating the combination of elebsiran and tobevibart for treating chronic hepatitis delta (CHD). The trial met its primary endpoint, with 44% of patients
achieving undetectable virus (HDV RNA TND) and normalized ALT levels at Week 48, compared to 0% in the delayed treatment group. A key secondary endpoint also showed 79% of patients achieved undetectable virus at Week 48. The regimen, administered monthly via subcutaneous injections, was well-tolerated, with most adverse events being mild to moderate and transient. These results were presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026. The company plans to submit a comprehensive global regulatory filing package to the U.S. FDA in mid-2027.
Why It's Important?
Chronic hepatitis delta (CHD) is the most severe form of chronic viral hepatitis, often leading to cirrhosis, liver failure, and liver-related death. Current treatment options in the U.S. and globally are limited. The high rate of undetectable virus achieved in the ECLIPSE 1 trial suggests that elebsiran and tobevibart could offer a significant new treatment option for patients, potentially reducing the risk of disease progression. The ability to achieve undetectable virus is considered a crucial virologic marker for improved clinical outcomes in CHD. This development could transform the lives of individuals suffering from this serious and progressive disease, offering hope for better long-term health outcomes and a reduction in liver-related mortality.
What's Next?
Vir Biotechnology plans to submit a comprehensive global regulatory filing package to the U.S. FDA in mid-2027, based on the positive results from ECLIPSE 1 and data from two other ongoing pivotal trials, ECLIPSE 2 and ECLIPSE 3, which are expected in the first quarter of 2027. The U.S. FDA has already granted Breakthrough Therapy and Fast Track designations for this combination therapy, indicating a recognition of the significant unmet need in CHD and the potential of this treatment. If approved, the monthly subcutaneous administration could offer a flexible and effective treatment option for patients. Vir Biotechnology has also entered into a licensing agreement with Norgine for commercialization in Europe, Australia, and New Zealand, subject to marketing authorizations.
Beyond the Headlines
The success of elebsiran and tobevibart highlights a broader trend in biopharmaceutical research towards developing targeted therapies that disrupt viral life cycles at multiple points. Elebsiran, a small interfering ribonucleic acid (siRNA), aims to degrade hepatitis B virus RNA transcripts, while tobevibart, a broadly neutralizing monoclonal antibody, inhibits viral entry and reduces circulating viral particles. This dual-mechanism approach could set a new standard for treating complex viral infections. The favorable safety profile and the potential for at-home administration could also improve patient adherence and quality of life, addressing not only the medical but also the practical challenges faced by patients with chronic diseases.
